Hans Wienk

The Netherlands Cancer Institute, Oncode Institute

Papers

2

Total Citations

12

H-Index

2

About

Hans Wienk is a researcher whose work sits at the intersection of biophysical techniques and drug discovery, with a particular focus on fragment-based lead discovery (FBLD) and protein characterization methodologies. His most recognized contributions center on the application of nano-Differential Scanning Fluorimetry (nano-DSF), a powerful thermal shift assay (TSA) platform used to investigate how a target protein's melting temperature responds to changes in its chemical environment, including buffer composition and small-molecule binding. Wienk's research has helped establish nano-DSF as a reliable and sensitive screening tool within the drug discovery pipeline, demonstrating its utility for identifying and validating fragment hits — small chemical compounds that serve as starting points for the development of therapeutic leads. By advancing the practical application of biophysical screening methods, his work contributes to accelerating early-stage drug discovery workflows. His 2021 publications on this subject have already begun attracting attention within the structural biology and medicinal chemistry communities, accumulating citations that reflect growing interest in accessible, high-quality biophysical screening approaches. For students and researchers entering the field of structure-based drug discovery, Wienk's work offers a rigorous and practical foundation in modern fragment screening technologies.

Research Focus

Key Achievements

2
H-Index
2
Papers
12
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
7 citations · 2021
📈 Most Prolific Year: 2021 (2 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: The Netherlands Cancer Institute, Oncode Institute

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 7 days ago